Overview

Chembio Diagnostics, Inc. develops and commercializes rapid point-of-care diagnostic tests for infectious diseases, including syphilis and HIV. The company is headquartered in Medford, Oregon, was founded in 1986, and has an estimated 100-200 employees with an estimated revenue band of $10-50 million. It is not publicly traded. The company serves medical, public health, and related healthcare markets. In February 2026, it received a $1.8 million CARB-X grant to develop a rapid diagnostic test for typhoid fever.

At a glance

What Chembio Diagnostics, Inc. makes

The company holds ISO 13485 certification and produces rapid diagnostic tests using lateral flow assay technology across infectious disease, respiratory, and tropical disease categories.

Certifications

Chembio Diagnostics, Inc. is associated with the following certifications in public sources. Confirm the certified scope for the specific plant producing your part:

• ISO 13485 — chembio.com

Latest developments

• 2026-10-23 — CHEMBIO DIAGNOSTIC SYSTEMS AWARDED $5.7 MILLION TO ADVANCE DPP® BIOTHREAT PANEL - Chembio Diagnostics, Inc. (chembio.com)

• 2026-08-13 — HHS has announced a $4 million initiative to expand rapid point-of-care syphilis testing and treatment—bringing testing closer to where women actually receive care. | Chembio Diagnostics, Inc. (linkedin.com)

• 2026-03-20 — QUALIGEN DIAGNOSTICS ANNOUNCE AGREEMENT WITH AFAXYS GPO TO EXPAND ACCESS TO FASTPACK® IP QUANTITATIVE hCG TESTING IN WOMEN'S HEALTH - Chembio Diagnostics, Inc. (chembio.com)

• 2026-02-06 — CHEMBIO RECEIVES $1.8 MILLION CARB-X GRANT TO DEVELOP A RAPID DIAGNOSTIC TEST FOR TYPHOID FEVER - Chembio Diagnostics, Inc. (chembio.com)

• 2026-02-05 — CARB-X to support development of typhoid fever diagnostic from Chembio - Carb-X (carb-x.org)

• 2026-01-22 — CHEMBIO ANNOUNCES DUAL FDA SUBMISSION OF DPP® SYPHILIS TnT ASSAY FOLLOWING BREAKTHROUGH DEVICE DESIGNATION - Chembio Diagnostics, Inc. (chembio.com)

Facilities

Chembio Diagnostics, Inc. is headquartered in Medford, Oregon. Public sources also reference these locations:

• Malaysia — nasdaq.com

Company details

Chembio is not publicly traded and has an estimated 100-200 employees, with its industry footprint centered on healthcare and point-of-care diagnostics. Chembio Diagnostics, Inc. was founded in 1986, has an estimated 100-200 employees, and is headquartered in Medford, Oregon. On the LightSource stability read it is rated "Established & active": 40 years in operation (founded 1986). Holds ISO 13485 certification(s) per public sources.

Frequently asked questions

What does Chembio Diagnostics, Inc. do?

Chembio Diagnostics, Inc. develops and commercializes rapid point-of-care diagnostic tests for infectious diseases, including syphilis and HIV. The company is headquartered in Medford, Oregon, was founded in 1986, and has an estimated 100-200 employees with an estimated revenue band of $10-50 million. It is not publicly traded. The company serves medical, public health, and related healthcare markets. In February 2026, it received a $1.8 million CARB-X grant to develop a rapid diagnostic test for typhoid fever.

Where is Chembio Diagnostics, Inc. headquartered?

Chembio Diagnostics, Inc. is headquartered in Medford, Oregon.

When was Chembio Diagnostics, Inc. founded?

Chembio Diagnostics, Inc. was founded in 1986.

How big is Chembio Diagnostics, Inc.?

Chembio Diagnostics, Inc. has an estimated 100-200 employees, with revenue in the $10-50M range (estimated).

What certifications does Chembio Diagnostics, Inc. hold?

Chembio Diagnostics, Inc. lists ISO 13485 on its website. Confirm the certified scope for the specific plant producing your part.

Related suppliers

Explore other suppliers in the LightSource directory:

• A&K Railroad Materials, Inc.

• A&T Europe Spa

• A.Celli Group

• AAC Clyde Space

• Abiogen Pharma S.P.A.

Last verified Nov 2026. Is this your company? Request a correction.